<DOC>
	<DOCNO>NCT00939211</DOCNO>
	<brief_summary>Chronic Obstructive Pulmonary Disease ( COPD ) chronic respiratory condition deteriorate lung function year . Patients COPD experience symptom shortness breath , cough sputum production . This study assess treatment effect inhalation three different single dos AZD9164 ( 100 , 400 1200 mcg ) one single dose tiotropium ( 18 mcg ) . One dose placebo give comparator . 25 patient participate study recruit Sweden . Each patient visit study doctor 9 time study , whereof 5 visit overnight visit . All examination , treatment follow-up free charge .</brief_summary>
	<brief_title>The Study Will Evaluate Effect AZD9164 Patients With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>A clinical diagnosis COPD FEV1 40 80 % predict normal value ( postbronchodilator ) post bronchodilator FEV1/FVC &lt; 70 % Any clinically relevant abnormal finding screen examination Any clinically significant disease disorder</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease ( COPD )</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>inhalation</keyword>
	<keyword>long-acting muscarinic receptor antagonist ( LAMA )</keyword>
</DOC>